Mepolizumab
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Mepolizumab: From Eosinophilic Diseases to Immune Thrombocytopenia
One-Sentence Summary
Mepolizumab is an anti-IL-5 monoclonal antibody internationally approved for eosinophilic conditions such as hypereosinophilic syndrome (HES), EGPA, and eosinophilic asthma. The TxGNN model predicts it may be effective for thrombocytopenia due to immune destruction, with 0 clinical trials and 1 publication (a single case report) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded in this evidence pack; internationally approved for eosinophilic diseases (HES, EGPA, eosinophilic asthma) |
| Predicted New Indication | Thrombocytopenia due to immune destruction |
| TxGNN Prediction Score | 99.66% |
| Evidence Level | L4 |
| New Zealand Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, mepolizumab is an anti-IL-5 monoclonal antibody that depletes eosinophils by blocking IL-5 signalling; its efficacy in eosinophilic diseases (HES, EGPA, eosinophilic asthma) has been proven, and mechanistically it may be applicable to immune-mediated conditions where eosinophil activity contributes to disease pathology.
The link to immune thrombocytopenia is indirect. The single supporting case report describes a steroid-resistant, hypereosinophilic immune disorder in which mepolizumab treatment coincided with resolution of a concomitant immune-mediated platelet destruction and microangiopathy. This suggests eosinophil-driven immune dysregulation may, in specific clinical contexts, contribute to platelet destruction — but this is a disease-specific, single-patient observation rather than evidence of a direct pharmacological mechanism acting on platelet production or clearance pathways.
Given the absence of formal MOA data and the reliance on one case report, the mechanistic rationale should be considered hypothesis-generating rather than established.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28648630 | 2018 | Case Report | Blood Cells, Molecules & Diseases | Resolution of a steroid-resistant, hypereosinophilic immune disorder with mepolizumab, with concomitant amelioration of a mixed thrombotic microangiopathy and immune-mediated platelet destruction |
New Zealand Market Information
Mepolizumab is not currently marketed or authorized in New Zealand; no license records are available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic link to immune thrombocytopenia rests on a single case report, and no clinical trials support this indication. A blocking data gap in TFDA package insert warnings/contraindications also prevents any initial safety assessment (S1).
To proceed, the following is needed:
- Official package insert / regulatory safety data (warnings, contraindications, DDI) for mepolizumab
- Confirmed mechanism of action (MOA) data from DrugBank or primary literature
- Additional clinical or mechanistic evidence linking IL-5/eosinophil pathways to immune-mediated platelet destruction, beyond the single existing case report
- Assessment of feasibility for New Zealand market entry given current unregistered status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.